Cleared Traditional

EnSite™ X EP System TactiFlex™ Ablation Catheter, Sensor Enabled™, Software Upgrade (K223094) - FDA 510(k) Clearance

Also marketed or referenced as:
EnSite™ X EP System TactiFlex™ Ablation Catheter, Sensor Enabled™, Software License

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K223094 · Abbott Medical · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2022
Decision
88d
Days
Class 2
Risk

K223094 is an FDA 510(k) clearance for the EnSite™ X EP System TactiFlex™ Ablation Catheter, Sensor Enabled™, Software U.... Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by Abbott Medical (St. Paul, US). The FDA issued a Cleared decision on December 27, 2022 after a review of 88 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Abbott Medical devices

Submission Details

510(k) Number K223094 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 30, 2022
Decision Date December 27, 2022
Days to Decision 88 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
37d faster than avg
Panel avg: 125d · This submission: 88d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 183
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K223094.
ZEUS System
K222389 · iRhythm Technologies, Inc. · Feb 2023
VX1+
K223516 · Volta Medical · Jan 2023
EndoPATx
K211557 · Itamar Medical , Ltd. · Dec 2022
STAR Apollo Mapping System
K220786 · Rhythm Al, Ltd. · Dec 2022
HemoSphere Advanced Monitor, Right Ventricular Pressure (RVP), Global Hypoperfusion Index (GHI)
K221704 · Edwards Lifesciences, LLC · Nov 2022
HemoSphere Advanced Monitoring Platform, HemoSphere ForeSight Oximeter cable
K223127 · Edwards Lifeciences, LLC · Nov 2022